GRI Bio (GRI)
Develops NKT-cell therapies for pulmonary fibrosis and autoimmune disease.
Something off on this page? Send us feedback.
Develops GRI-0621 for idiopathic pulmonary fibrosis and GRI-0803 for autoimmune disease by regulating distinct NKT-cell populations. The pre-revenue company retains worldwide rights and expects successful development to support commercialization, licensing, or collaboration economics.
Develops GRI-0621, an oral candidate that inhibits iNKT-cell activity, for idiopathic pulmonary fibrosis, and GRI-0803, an oral activator of dNKT cells, for autoimmune disease, initially systemic lupus erythematosus and lupus nephritis. The former has completed an early clinical trial; the latter remains in IND-enabling development. The company retains worldwide rights and expects future commercialization, licensing, or collaboration economics if its programs succeed.
Operates from La Jolla with a focused internal team while relying on consultants, contract research organizations, contract manufacturers, investigators, and suppliers. Its near-term effort is concentrated on GRI-0621, whose further development requires FDA clearance and substantial capital or a strategic partner; it has no approved product, commercial infrastructure, or significant operating revenue.
Company facts
No analyst consensus on record.
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $10.9M · Total debt $44.0K · Total assets $11.4M · Shareholders' equity $10.3M
- Revenue
- $0
- Operating income
- −$1.6M
- Net income
- −$1.6M
No dividends on record.
| Institutions | 104.17% | 93.6K shares | |
|---|---|---|---|
| 11 holders · as of Jun 30, 2026 | |||
| Adds to | 104.17% | ||
89.8K company shares as of Sep 2, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
Two share counts disagree (2.19M in the company's Sep 23, 2026 report, 89.8K elsewhere); stakes use the report.
These groups come from separate filings that can overlap, so they add to 104.17%; nothing is left for Other.
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
HRT Financial LPInstitution | 32.04% | 28,784 | as of Jun 30, 2026 |
Vanguard Capital Management LLCInstitution | 23.79% | 21,368 | as of Jun 30, 2026 |
Geode Capital Management, LLCInstitution | 15.44% | 13,869 | as of Jun 30, 2026 |
Citadel Advisors LLCInstitution | 14.89% | 13,376 | as of Jun 30, 2026 |
Morgan StanleyInstitution | 9.73% | 8,737 | as of Jun 30, 2026 |
Insider tradesForm 4
Nothing filed in the last 12 months.
- Avalyn Pharma
IPF challenge from inhaled nintedanib and combination regimens.
- Contineum Therapeutics
Head-to-head oral small-molecule development in idiopathic pulmonary fibrosis.
- GSK (ADR)
Marketed SLE and lupus-nephritis biologic with global commercial reach.
- Aurinia Pharmaceuticals
Approved oral lupus-nephritis therapy establishes a high clinical bar.
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| GRI Bio | $2.08 | +1.50% | $184.2K | — | — | — | — |
| Avalyn Pharma | $29.67 | −8.57% | $1.44B | — | — | — | — |
| Contineum Therapeutics | $12.72 | −5.05% | $504.1M | — | — | — | — |
| GSK (ADR) | $49.74 | −1.93% | $101.62B | 16.1 | 9.2 | 2.3 | +5.3% |
| Aurinia Pharmaceuticals | $16.36 | −1.89% | $2.14B | 7.3 | 21.2 | 6.9 | +18.9% |
| Median | 11.7 | 15.2 | 4.6 | +12.1% |